Michael A Pulsipher
Overview
Explore the profile of Michael A Pulsipher including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
249
Citations
8494
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
2.
Jambon S, Sun J, Barman S, Muthugounder S, Bito X, Shadfar A, et al.
Blood Cancer Discov
. 2024 Dec;
6(1):55-72.
PMID: 39624992
Our study demonstrates the use of "IF-THEN" SynNotch-gated CAR-T cells targeting CD33 and CD123 in AML reduces off-tumor toxicity. This strategy enhances T-cell phenotype, improves expansion, preserves HSPCs, and mitigates...
3.
Iftikhar R, DeFilipp Z, DeZern A, Pulsipher M, Bejanyan N, Burroughs L, et al.
Transplant Cell Ther
. 2024 Sep;
30(12):1155-1170.
PMID: 39307421
Allogeneic hematopoietic cell transplantation (HCT) is a potentially curative treatment for severe aplastic anemia (SAA). Existing guidance about HCT in SAA is primarily derived from expert reviews, registry data and...
4.
Eapen M, Antin J, Tolar J, Arai S, Horwitz M, Kou J, et al.
EClinicalMedicine
. 2024 Sep;
76:102819.
PMID: 39290639
Background: Almost all acquired severe aplastic anaemia is immune mediated and characterised by hypocellular bone marrow and ≥2 affected haematopoietic lineages. The optimal preparartive regimen for unrelated donor transplantation remains...
5.
Miranda M, Tsalatsanis A, Trotter J, Arnold D, Squire J, Kidd S, et al.
Clin Immunol
. 2024 Sep;
268:110364.
PMID: 39278553
No abstract available.
6.
Annesley C, Lamble A, Summers C, Pulsipher M, Wayne A, Rivers J, et al.
Blood Adv
. 2024 Aug;
PMID: 39133891
Infants with B-cell acute lymphoblastic leukemia (B-ALL) continue to have significantly worse outcomes compared to older children with B-ALL, and those with relapsed or refractory (R/R) infant ALL have especially...
7.
8.
Dvorak C, Long-Boyle J, Holbrook-Brown L, Abdel-Azim H, Bertaina A, Vatsayan A, et al.
Blood Adv
. 2024 Jul;
8(23):6003-6014.
PMID: 39042892
We hypothesized that the inferior disease-free survival (DFS) seen in older patients who underwent αβ-T-cell/CD19-depleted (AB-TCD) haploidentical hematopoietic cell transplantation (HCT) for hematologic malignancies is caused by excessive exposure to...
9.
Zinter M, Dvorak C, Mayday M, Reyes G, Simon M, Pearce E, et al.
Nat Med
. 2024 May;
30(7):1982-1993.
PMID: 38783139
Hematopoietic cell transplantation (HCT) uses cytotoxic chemotherapy and/or radiation followed by intravenous infusion of stem cells to cure malignancies, bone marrow failure and inborn errors of immunity, hemoglobin and metabolism....
10.
Muffly L, Liang E, Dolan J, Pulsipher M
Blood
. 2024 May;
144(3):253-261.
PMID: 38728375
Measurable residual disease (MRD) evaluation by multiparameter flow cytometry (MFC) or quantitative polymerase chain reaction methods is an established standard of care for assessing risk of relapse before or after...